Anatabine: Difference between revisions
Appearance
Content deleted Content added
Updating {{drugbox}} (no changed fields - added verified revid - updated 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'DrugBank_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia talk:WikiProject |
reference given for the claim |
||
(102 intermediate revisions by 46 users not shown) | |||
Line 1: | Line 1: | ||
{{short description|Chemical compound}} |
|||
{{cs1 config|name-list-style=vanc}} |
|||
{{Drugbox |
{{Drugbox |
||
| Watchedfields = changed |
|||
| verifiedrevid = |
| verifiedrevid = 451607368 |
||
| IUPAC_name = [2R,(+)]-1,2,3,6-Tetrahydro-2,3'-bipyridine |
| IUPAC_name = [2R,(+)]-1,2,3,6-Tetrahydro-2,3'-bipyridine |
||
| image = Anatabine.svg |
| image = Anatabine.svg |
||
<!--Clinical data--> |
<!--Clinical data--> |
||
| tradename = |
| tradename = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|correct|??}} |
|||
| CAS_number = 581-49-7 |
| CAS_number = 581-49-7 |
||
| ChEBI = 2705 |
|||
| ChEMBL = 3640772 |
|||
| KEGG = C10126 |
|||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = 5PP654XB7D |
|||
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
||
| ChemSpiderID = 10910 |
| ChemSpiderID = 10910 |
||
| PubChem = 11388 |
|||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=10 | H=12 | N=2 |
|||
| chemical_formula = C<sub>10</sub>H<sub>12</sub>N<sub>2</sub> |
|||
| molecular_weight = 160.22 g/mol |
|||
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChI = 1S/C10H12N2/c1-2-7-12-10(5-1)9-4-3-6-11-8-9/h1-4,6,8,10,12H,5,7H2/t10-/m0/s1 |
| StdInChI = 1S/C10H12N2/c1-2-7-12-10(5-1)9-4-3-6-11-8-9/h1-4,6,8,10,12H,5,7H2/t10-/m0/s1 |
||
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}} |
||
| StdInChIKey = SOPPBXUYQGUQHE-JTQLQIEISA-N |
| StdInChIKey = SOPPBXUYQGUQHE-JTQLQIEISA-N |
||
| SMILES = c1cc(cnc1)[C@@H]2CC=CCN2 |
|||
}} |
}} |
||
'''Anatabine''' (uh-nat-uh-been,-bin) is one of the minor [[ |
'''Anatabine''' (uh-nat-uh-been,-bin) is one of the minor [[alkaloid]]s found in plants in the family [[Solanaceae]], which includes the [[tobacco plant]] and [[tomato]]. Commercial tobacco plants typically produce alkaloids at levels between 2% and 4% of total dry weight,<ref>{{cite journal | vauthors = Laszlo C, Kaminski K, Guan H, Fatarova M, Wei J, Bergounioux A, Schlage WK, Schorderet-Weber S, Guy PA, Ivanov NV, Lamottke K, Hoeng J | title = Fractionation and Extraction Optimization of Potentially Valuable Compounds and Their Profiling in Six Varieties of Two ''Nicotiana'' Species | journal = Molecules | volume = 27 | issue = 22 | page = 8105 | date = November 2022 | pmid = 36432206 | pmc = 9694777 | doi = 10.3390/molecules27228105 | doi-access = free }}</ref> with [[nicotine]] accounting for about 90% of the total alkaloid content, and the related compounds anatabine, [[nornicotine]], and [[anabasine]] making up nearly all the rest.<ref name=Dewey>{{cite journal | vauthors = Dewey RE, Xie J | title = Molecular genetics of alkaloid biosynthesis in Nicotiana tabacum | journal = Phytochemistry | volume = 94 | pages = 10–27 | date = October 2013 | pmid = 23953973 | doi = 10.1016/j.phytochem.2013.06.002 | bibcode = 2013PChem..94...10D }}</ref> These compounds are thought to be biologically active, and part of plants' natural defense system against insects.<ref name=Dewey/> |
||
Anatabine has [[anti-inflammatory]] activity partly through inhibition of [[STAT3]] phosphorylation in vitro and in vivo.<ref name="pmid23178521">{{cite journal |vauthors=Paris D, Beaulieu-Abdelahad D, Abdullah L, Bachmeier C, Ait-Ghezala G, Reed J, Verma M, Crawford F, Mullan M |title=Anti-inflammatory activity of anatabine via inhibition of STAT3 phosphorylation |journal=[[European Journal of Pharmacology]] |volume=698 |issue=1–3 |pages=145–53 |date=January 2013 |pmid=23178521 |doi=10.1016/j.ejphar.2012.11.017 |issn=}}</ref> |
|||
== Pharmacology == |
|||
On a [[biochemical]] level, it appears to be active against certain [[nicotinic acetylcholine receptors]].<ref name=Mello/> |
|||
==Commercial development== |
|||
[[Star Scientific]] developed and sold the compound as a [[dietary supplement]] primarily through GNC up until mid 2014. Subsequently, Rock Creek Pharmaceuticals (formerly a subsidiary of [[Star Scientific]]), headquartered in Florida, began developing anatabine as a [[pharmaceutical drug|drug]].<ref name=Forbes>{{cite web | first = David | last = Kroll | work = Forbes | date = 31 January 2014 | url = https://www.forbes.com/sites/davidkroll/2014/01/31/whats-the-dope-on-anatabine-in-star-scientifics-anatabloc-and-cigrx/ | title = The McDonnell Scandal: What's The Dope Behind Star Scientific Supplement Products? }}</ref><ref name=Gabriel>{{cite web | first = Trip | last = Gabriel | work = New York Times | date = 21 January 2014 | url = https://www.nytimes.com/2014/01/22/us/former-virginia-governor-and-his-wife-are-indicted.html | title = Ex-Governor of Virginia Is Indicted on Charges Over Loans and Gifts }}</ref> The dietary supplements were known as Anatabloc and CigRx; the company has also marketed cosmetics with the Anatabloc brand.<ref name=Forbes/> Rock Creek had been working on synthetic methods to scale up production of anatabine and has funded [[Pre-clinical development|pre-clinical]] and [[clinical research|clinical]] research in several [[Indication (medicine)|indications]].<ref name=Forbes/> |
|||
In 2013 the FDA warned Star Scientific for unlawfully promoting CigRx and Anatabloc before anatabine was proved to be safe.<ref>{{cite news | url = http://washington.cbslocal.com/2013/12/31/fda-says-star-scientific-illegally-marketing-products/ | title = FDA Says Star Scientific Illegally Marketing Products | work = CBS News | date = December 31, 2013}}</ref><ref>[https://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2013/ucm379639.htm FDA Warning Letter]</ref> Subsequently, new management and a mostly new board under the banner of Rock Creek Pharmaceuticals withdrew the dietary supplement because of the FDA's concerns. |
|||
In 2013, Star Scientific became embroiled in political scandal, when news broke that the governor of Virginia, [[Bob McDonnell]], and his wife had received significant loans and gifts from [[Jonnie Williams]] Sr, the CEO of the company. They were found to have helped the company in several ways like arranging meetings with top officials and giving special favors from the state government.<ref name=Gabriel/> Williams resigned in 2014 and the company changed its name and restructured its board and management at the end of 2013 due to the scandal.<ref name=Forbes/> |
|||
There have been hypotheses that minor tobacco constituents and other non-nicotine therapies may be beneficial in fighting nicotine withdrawal.<ref name="pmid19939867">{{cite journal | author = Mattioli L, Perfumi M | title = Evaluation of Rhodiola rosea L. extract on affective and physical signs of nicotine withdrawal in mice | journal = J. Psychopharmacol. (Oxford) | volume = 25 | issue = 3 | pages = 402–10 | year = 2011 | month = March | pmid = 19939867 | doi = 10.1177/0269881109348166 }}</ref> Many studies have been conducted investigating the effects of smoking on MAO activity.<ref name="pmid8602220">{{cite journal | author = Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, MacGregor R, Alexoff D, Shea C, Schlyer D, Wolf AP, Warner D, Zezulkova I, Cilento R | title = Inhibition of monoamine oxidase B in the brains of smokers | journal = Nature | volume = 379 | issue = 6567 | pages = 733–6 | year = 1996 | month = February | pmid = 8602220 | doi = 10.1038/379733a0 }}</ref><ref name="pmid8943061">{{cite journal | author = Fowler JS, Volkow ND, Wang GJ, Pappas N, Logan J, Shea C, Alexoff D, MacGregor RR, Schlyer DJ, Zezulkova I, Wolf AP | title = Brain monoamine oxidase A inhibition in cigarette smokers | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 93 | issue = 24 | pages = 14065–9 | year = 1996 | month = November | pmid = 8943061 | pmc = 19495 | doi = }}</ref><ref name="pmid16884739">{{cite journal | author = van Amsterdam J, Talhout R, Vleeming W, Opperhuizen A | title = Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction | journal = Life Sci. | volume = 79 | issue = 21 | pages = 1969–73 | year = 2006 | month = October | pmid = 16884739 | doi = 10.1016/j.lfs.2006.06.010 }}</ref><ref name="pmid3588781">{{cite journal | author = Norman TR, Chamberlain KG, French MA | title = Platelet monoamine oxidase: low activity in cigarette smokers | journal = Psychiatry Res | volume = 20 | issue = 3 | pages = 199–205 | year = 1987 | month = March | pmid = 3588781 | doi = 10.1016/0165-1781(87)90079-5 }}</ref> |
|||
However, the accumulated legal costs from the defense of Jonnie Williams in the McDonnell scandal overwhelmed the company’s finances and it filed for bankruptcy in 2016.<ref>{{Cite web|url=http://www.biospace.com/News/with-a-history-of-political-corruption-rock-creek/434072|title=With a History of Political Corruption Rock Creek Pharma Files for Bankruptcy|website=www.biospace.com|access-date=2017-08-17}}</ref> As a consequence, the development and clinical trials of anatabine were halted indefinitely. |
|||
Anatabine is one of the ingredients in the smoking alternative dietary supplement, CiGRX, developed by Rock Creek Pharmaceuticals.<ref name="urlCiGRX">{{cite web | url = http://www.cigrx.com | title = CiGRX | publisher = Star Scientific, Inc | accessdate = 2011-09-06 }}</ref> The use of anatabine rather than nicotine replacement therapy is related to the half-lives of nicotine and anatabine. The latency of needing a cigarette (LTNC) among regular smokers was less than two hours<ref name="pmid21402261">{{cite journal | author = Ursprung WW, Morello P, Gershenson B, DiFranza JR | title = Development of a measure of the latency to needing a cigarette | journal = J Adolesc Health | volume = 48 | issue = 4 | pages = 338–43 | year = 2011 | month = April | pmid = 21402261 | doi = 10.1016/j.jadohealth.2010.07.011 | url = }}</ref> compared to the half-life of anatabine which is 10 hours.<ref name="Payton1999" /> |
|||
== Research == |
|||
Rock Creek Pharmaceuticals has also developed Anatabloc, a product that targets inflammation.<ref name="urlAnatabloc">{{cite web | url = http://www.anatabloc.com | title = Anatabloc | publisher = Star Scientific, Inc | accessdate = 2011-09-06 }}</ref> [[The Roskamp Institute]] in Sarasota, Florida, has worked with Rock Creek Pharmaceuticals to study the effects of the anatabine compound on inflammatory diseases and disorders. Roskamp findings can be viewed at The Roskamp Institute Website.<ref name="urlRoskamp Institute | Role of Anatabine as an anti-inflammatory agent">{{cite web | url = http://www.rfdn.org/inflammaging.html | title = Role of Anatabine as an anti-inflammatory agent | date = | work = | publisher = Roskamp Institute | quote = | accessdate = 2011-09-06 }}</ref> |
|||
Anatabine has been studied in animal models and in cells to see if it might be useful for treating [[nicotine addiction]] and [[inflammation]], and has been studied in models of diseases characterized by inflammation, such as [[Alzheimer's disease]],<ref name="pmid26230317">{{cite journal |vauthors=Verma M, Beaulieu-Abdelahad D, Ait-Ghezala G, Li R, Crawford F, Mullan M, Paris D |title=Correction: Chronic Anatabine Treatment Reduces Alzheimer's Disease (AD)-Like Pathology and Improves Socio-Behavioral Deficits in a Transgenic Mouse Model of AD |journal=[[PLOS One]] |volume=10 |issue=7 |pages=e0134776 |date=2015 |pmid=26230317 |pmc=4521847 |doi=10.1371/journal.pone.0134776 |issn=|doi-access=free |bibcode=2015PLoSO..1034776V }}</ref> [[thyroiditis]],<ref>{{cite journal | vauthors = Schmeltz LR, Blevins TC, Aronoff SL, Ozer K, Leffert JD, Goldberg MA, Horowitz BS, Bertenshaw RH, Troya P, Cohen AE, Lanier RK, Wright C | display-authors = 6 | title = Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: a randomized controlled clinical trial | journal = The Journal of Clinical Endocrinology and Metabolism | volume = 99 | issue = 1 | pages = E137-42 | date = January 2014 | pmid = 24178792 | pmc = 3928963 | doi = 10.1210/jc.2013-2951 }}</ref> and [[multiple sclerosis]].<ref name=Mello>{{cite journal | vauthors = Mello NK, Fivel PA, Kohut SJ, Caine SB | title = Anatabine significantly decreases nicotine self-administration | journal = Experimental and Clinical Psychopharmacology | volume = 22 | issue = 1 | pages = 1–8 | date = February 2014 | pmid = 24490707 | doi = 10.1037/a0035409 | s2cid = 15879738 }} Note: content is supported by discussion section which provides a brief review of research to date.</ref> Anatabine cream was helpful in managing mild to moderate [[rosacea]].<ref name="pmid24348385">{{cite journal |vauthors=Lanier RK, Cohen AE, Weinkle SH |title=Effects of a facial cream containing the minor alkaloid anatabine on improving the appearance of the skin in mild to moderate rosacea: an open-label case series study |journal=[[Case Reports in Dermatology]] |volume=5 |issue=3 |pages=347–56 |date=2013 |pmid=24348385 |pmc=3861860 |doi=10.1159/000357019|issn=}}</ref> An internet based survey showed 82% users reported a benefit from anatabine supplementation for one or more joint pain conditions.<ref name="pmid24250235">{{cite journal |vauthors=Lanier RK, Gibson KD, Cohen AE, Varga M |title=Effects of dietary supplementation with the solanaceae plant alkaloid anatabine on joint pain and stiffness: results from an internet-based survey study |journal=[[Clinical Medicine Insights. Arthritis and Musculoskeletal Disorders]] |volume=6 |issue= |pages=73–84 |date=2013 |pmid=24250235 |pmc=3825642 |doi=10.4137/CMAMD.S13001 |issn=}}</ref> |
|||
== See also == |
|||
Anatabine's potential in fighting Alzheimer's disease and other anti-inflammatory illnesses is being studied.<ref name="urlRoskamp Institute | Role of Anatabine as an anti-inflammatory agent">{{cite web | url = http://www.rfdn.org/inflammaging.html | title = Role of Anatabine as an anti-inflammatory agent | date = | work = | publisher = Roskamp Institute | quote = | accessdate = 2011-09-06 }}</ref> |
|||
* [[Anatalline]] |
|||
* [[Anabaseine]] |
|||
* [[Myosmine]] |
|||
== References == |
== References == |
||
{{Reflist|2}} |
{{Reflist|2}} |
||
[[Category: |
[[Category:Pyridine alkaloids]] |
||
[[Category:Alkaloids]] |
[[Category:Alkaloids found in Solanaceae]] |
||
[[Category: |
[[Category:3-Pyridyl compounds]] |